更新于：2024-06-19
Nadroparin Calcium
那屈肝素钙
更新于：2024-06-19
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞典 (1997-06-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
关联
68
项与 那屈肝素钙 相关的临床试验A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery: a Single-center, Prospective, Observational Cohort Study
评价那屈肝素钙注射液在中国成年健康受试者中的一项单中心、随机、开放、空腹条件下单次给药、两制剂、两周期交叉的生物等效性研究
评估受试制剂那屈肝素钙注射液与参比制剂（速碧林®）在健康成年参与者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
100 项与 那屈肝素钙 相关的临床结果
登录后查看更多信息
100 项与 那屈肝素钙 相关的转化医学
登录后查看更多信息
100 项与 那屈肝素钙 相关的专利（医药）
登录后查看更多信息
797
项与 那屈肝素钙 相关的文献（医药）2024-03-06The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians4区 · 医学
Myasthenia gravis and covid-19 in pregnancy: a review of the literature and case series report
4区 · 医学
Review
作者: Neykova, Konstantsa Krassimirova ; Ignatov, Peter Nikolaev ; Milanova, Milena
OBJECTIVES:
The aim of our study was to investigate the interrelations of symptoms, clinical outcomes and treatment regimens in pregnant women, diagnosed with myasthenia gravis and superimposed COVID-19 infection.
METHODS:
We conducted an observational retrospective study between August, 2020 and July, 2021. Five patients with preexisting MG and superimposed COVID- infection were included in our study. We investigated the duration of MG, the antibody patient status, any present comorbidities, MG baseline treatment and MG severity class prior to the COVID-19 infection, MG severity class and treatment during the COVID-infection, and last but not least, the maternal and fetal clinical outcome.
RESULTS:
None of the participants were hospitalized as they were treated under quarantine at their homes. The most frequently reported complaints were anosmia, headache and fever, which were observed in 3 out of 5 patients. The MG severity was evaluated twice - before and after the quarantine period. Progression to a more advanced stage was found in 2 of our 5 patients. Three of the patients did not require any changes in the prescribed baseline MG treatment. In 2 patients the pyridostigmine dosage had to be increased. One patient received azithromycin and 4 patients were given LMWH (nadroparin) as specific anti-COVID measures. All patients fully recovered and gave birth to healthy newborns.
CONCLUSION:
To our knowledge, this is the first study on pregnant MG patients with superimposed COVID-19 infection. Based on our observations in this study it would seem that the coexistence of MG and COVID-19 infection in pregnancy does not elicit exacerbation in neither of those conditions. Further research is needed to confirm or challenge these findings, especially with the prospects of new virus variants emerging in the future.
2024-01-01Hemodialysis international. International Symposium on Home Hemodialysis
Effect of conventional hemodialysis on the apixaban plasma concentration
Article
作者: de Rouw, Nikki ; Windsant, Annemieke M A Vermeulen ; Kerckhoffs, Angele P M ; Poel, Tim ; Péquériaux, Nathalie C V ; van de Kerkhof, Daan ; van Marum, Rob J
Abstract:
Purpose:
Apixaban is a factor Xa inhibitor used in patients undergoing hemodialysis treatment. The objective of this study is to investigate the effect of hemodialysis on apixaban plasma concentrations.
Methods:
This observational study is on patients treated with apixaban 2.5 mg twice daily on conventional hemodialysis with standard low‐molecular‐weight heparin (LMWH) anticoagulation (nadroparin 3800–7600 IU). Plasma blood samples were collected before starting dialysis (t1), 2 h after starting dialysis (t2), and directly after dialysis (t3). Apixaban concentration was measured before and after dialysis. Anti‐Xa activity was measured for all three samples.
Results:
A significant difference was observed between the apixaban concentration before and after dialysis (mean before dialysis 141.03 ng/mL; mean after dialysis 102.71 ng/mL; p = 0.003). Nonetheless, both apixaban plasma concentrations and anti‐Xa levels remained within the reference range. Anti‐Xa levels had a strong correlation with the apixaban concentrations (r = 0.935, p = 0.000). Thus, anti‐Xa activity might be used as a surrogate for apixaban plasma concentration.
Conclusion:
There seems to be no need for dose adjustments of apixaban; co‐administration of LMWH next to apixaban might also be unnecessary.
2023-11-01Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
Probable rivaroxaban-induced erythema multiforme in children: A case report
作者: Liu, Ying ; Liu, Xiaoya ; Fu, Zhengran ; Zhan, Min ; Cheng, Xiaoling ; Liu, Ting ; Cao, Zhongqiang
Background: Limited data exists on the use of rivaroxaban for the treatment of pediatric patients. This report presents a case of probable rivaroxaban-induced Erythema Multiforme in Children. Case Summary: A female patient aged 5.5 years with antiphospholipid syndrome (APS) was administered oral rivaroxaban tablets 2.5 mg twice a day for 16 days. Subsequently, the patient developed a slight itching sensation on both feet and buttocks without an apparent cause. The following day, erythema multiforme appeared across the body in a scattered pattern. The erythema presented higher than the skin surface and partially merged into areas of the skin. Following an increase in the extent and degree of the erythema, all oral medications were ceased. Treatment with dexamethasone sodium phosphate injection, mometasone furoate cream, and mucopolysaccharide polysulfate cream resulted in an improvement of erythema multiforme. The erythema diminished and did not deteriorate subsequent to changing from rivaroxaban tablets to warfarin sodium tablets, and receiving nadroparin calcium injection.
100 项与 那屈肝素钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 静脉血栓形成 | 瑞典 | 1997-06-24 | |
| 不稳定型心绞痛 | - | - | - |
| 血栓形成 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血栓栓塞 | 临床1期 | 中国 | 2016-02-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 築簾繭窪衊積選鏇醖衊(廠構憲衊範觸鏇齋鏇糧) = 網網壓夢製艱製壓夢獵 範襯糧艱顧製壓鏇顧鑰 (範網積廠窪鏇糧觸築艱 ) | 积极 | 2022-06-02 | ||
築簾繭窪衊積選鏇醖衊(廠構憲衊範觸鏇齋鏇糧) = 衊遞膚淵鹹顧鏇窪範構 範襯糧艱顧製壓鏇顧鑰 (範網積廠窪鏇糧觸築艱 ) 更多 | |||||||
N/A | anticardiolipin - | anti-annexin V - | anti-b2-GPI - ... 更多 | 146 | 繭廠積構鑰範艱淵鏇壓(淵繭憲壓積鹹築鏇醖鬱) = 襯蓋鏇夢醖壓簾夢繭淵 醖衊鏇餘廠獵觸廠鬱構 (淵構鑰遞範構壓願觸築 ) 更多 | - | 2020-07-12 | ||
临床2/3期 | - | 467 | 築糧醖構膚範鏇繭衊壓(壓餘齋餘糧鹽築鏇選鹹) = 鹽簾廠餘選獵蓋鬱壓糧 鏇醖壓糧齋衊遞構獵觸 (齋膚範醖鬱築憲構鏇襯, 1.2 ~ 23.6) | 积极 | 2017-04-01 | ||
築糧醖構膚範鏇繭衊壓(壓餘齋餘糧鹽築鏇選鹹) = 繭顧壓繭鏇繭廠餘鹽淵 鏇醖壓糧齋衊遞構獵觸 (齋膚範醖鬱築憲構鏇襯, 1.4 ~ 80.7) | |||||||
临床3期 | 1,150 | 鬱窪廠膚蓋鏇製廠觸獵(鬱艱簾夢鹹鹽積遞鏇鹽) = 鑰獵選襯築顧鏇糧膚鏇 鹽鏇蓋餘淵壓築衊膚製 (願獵艱築簾鏇廠鏇築膚 ) 更多 | 积极 | 2009-10-01 | |||
Placebo | 鬱窪廠膚蓋鏇製廠觸獵(鬱艱簾夢鹹鹽積遞鏇鹽) = 積願積夢積鹹積齋鹹襯 鹽鏇蓋餘淵壓築衊膚製 (願獵艱築簾鏇廠鏇築膚 ) 更多 | ||||||
N/A | 皮肤真菌反应 lymphocyte transformation test (LTT) | nadroparin-activated basophils (BAT) | - | 鏇襯窪淵醖廠構艱積餘(範窪繭鏇糧願夢蓋鹹餘) = can induce immunologically mediated adverse effects, especially thrombocytopenia, but also cutaneous reactions, as demonstrated in our case 顧鹹觸膚餘憲遞選構網 (鑰糧醖窪積鹽淵夢窪願 ) 更多 | 积极 | 2003-03-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用